Deutsche Bank maintained its Eli Lilly LLY Hold rating and $38.50 price target in a research report published today.
In the report, Deutsche Bank states, " The upside risks to our Hold rating are that Effient sales exceed expectations, or the company
does a large merger, both of which are unlikely, in our view. The primary downside risks are disappointing commercial sales for Effient, a slowdown for Cymbalta, additional pipeline disappointments, and a failure to achieve targeted cost-cutting measures."
Shares of Eli Lilly closed today at $39.32, up 3.01% from Wednesday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in